Parliament Workbench
Data: Official Report to 19 Nov 2026

Official Report · Committee

Continued Petitions

Myalgic Encephalomyelitis (Treatment) (PE1690)

Thursday 19 December 2019 Public Petitions Committee About 08:45–09:15 Petitions 28 contributions · 7 speakers

Speakers

Choose an MSP to read only their contributions

The record

28 contributions
Johann Lamont Lab The Convener · Glasgow
link

I welcome everyone to the 22nd meeting of the Public Petitions Committee in 2019. The first and only item on our agenda is consideration of continued petitions.

The first petition for consideration today is PE1690, which calls for a review of treatment of people with myalgic encephalomyelitis in Scotland. The petition was lodged by Emma Shorter on behalf of #MEAction Scotland. When we previously considered the petition in May 2019, the committee agreed to invite the Cabinet Secretary for Health and Sport to give evidence, and I am delighted to welcome her today, as well as her officials from the Scottish Government. Dr Catherine Calderwood is the chief medical officer and Anita Stewart is team leader for clinical priorities.

I invite the cabinet secretary to make a brief opening statement before we move on to questions.

Jeane Freeman SNP The Cabinet Secretary for Health and Sport · Carrick, Cumnock and Doon Valley
link

Thank you, convener, and good morning to you and committee members. As you know, I wrote to the committee in September. The opening statement that I am about to make touches on some of the points in my letter, but it also covers the recently published neurological care and support in Scotland plan.

I start by reiterating our commitment to ensuring that everyone in Scotland who is living with a neurological condition, including ME, is able to access the best possible care and support and benefit from healthcare services that are safe, effective and person centred.

Since I spoke in January, there have been a number of developments that are relevant to the petition. In March, Healthcare Improvement Scotland published its revised “General standards for neurological care and support”, which we worked closely in partnership to deliver. The revised standards, which are based on the 2018 health and social care standards, represent significant collaboration across statutory bodies, third sector organisations and people with lived experience. The standards stipulate that people should expect to receive the same high-quality service from health and social care organisations that support them, regardless of their condition, geographical location or individual circumstances.

Yesterday we launched Scotland’s first framework for action on neurological care and support, and over the next five years we will work closely with partners including HIS, NHS Education for Scotland and key stakeholders across the neurological community to implement the 17 commitments to improve access to care and support. The framework is not condition specific, but we recognise ME as a neurological condition. During the development of the framework, we heard from the ME community through both the lived experience survey that was led by the Health and Social Care Alliance Scotland and the responses to our public consultation.

I hope that people who are affected by ME will identify with the framework’s five aims, which include ensuring equitable and timely access to high standards of person-centred care, establishing a sustainable workforce model and improving the co-ordination of care and support for people with neurological conditions. Underpinning those aims are commitments setting out the actions that we will take. For example, the petition seeks further research on ME, and the neurological framework outlines how we will support the neurological research agenda.

As I highlighted in my letter to you in September, the chief scientist office has been in dialogue with ME research organisations, researchers and various ME third sector groups to explore how we can specifically do that for ME, including with opportunities through the existing research that we are co-funding at the University of Edinburgh. We have also told ME organisations that we would consider a funding proposal from them to contribute support to the creation of a priority-setting partnership through the James Lind Alliance, and I understand that organisations see the value in pursuing that.

This is also partly about understanding the prevalence of neurological conditions—I know that the petitioner is keen that we make progress on that—so another commitment is to improve the recording of neurological conditions such as ME in people’s routine health and care records so that they are visible to appropriate services. We have prioritised the continuation of the prevalence work that we started with the Information Services Division in 2018, recognising that, to make progress, we are subject to developments that are under way, particularly with regard to primary care systems. I still expect progress to be made over the next year.

On awareness of the information and resources that are available on neurological conditions for both patients and professionals, we have committed to actions that support shared decision making and access to supported self-management, building on and learning from existing provision including peer support networks. My officials have been supporting and will continue to support ME organisations to explore opportunities with NHS Education for Scotland and other bodies to develop training materials for professionals about ME. That includes understanding the context of undergraduate, postgraduate and continuous development resources generally for neurological conditions.

I hope that the petitioner will also welcome the focus that the framework will bring to the testing and evaluation of generic community-based, multidisciplinary team models to assess innovative ways of delivering care, including new roles and new arrangements for co-ordinating care and support for people with neurological conditions. Another relevant commitment is our intention to work with others to develop nationally agreed, regionally and locally applied guidelines for health services and referral pathways. In addition, we will explore the potential of national care frameworks to inform neurological care and support. I know that some of the third sector ME organisations are already considering the potential of an existing framework for another condition and how it might be beneficial to people with ME. When implementing the commitment from the framework, we will be mindful of the need to consider how different types of neurological conditions, such as ME, can be represented in that work.

Another area that is relevant to the petition is the commitment to improve the use of digital technology to ensure that integrated services seamlessly meet the needs of people with neurological conditions and those who provide care and support to them. It has been demonstrated that the introduction of technology can make a huge difference for some neurological conditions, and we will look to learn from and build on that over the next years.

Implementation of the framework and the improvement actions is being informed by quality management, and specifically quality planning, control, assurance and improvement that is linked to leadership and learning systems and processes that will promote collaboration with people who have lived experience and are involved with the services.

Over the past year, my officials have been in regular communication with the petitioner, Emma Shorter, and #MEAction, as well as with healthcare professionals with relevant experience, individuals who are living with the condition and other organisations that represent those who are affected by ME. As I highlighted in my letter to the committee, we have commissioned two pieces of work. The first is an updated needs assessment by the Scottish Public Health Network to understand the practices and provision for ME in Scotland, which will cover both adults and children and young people. The second is a views-gathering exercise facilitated by the Scottish health council to find out what good care and support would look like for people with lived experience of ME. On advice from ME organisations, we have kept the scope of that second piece of work to adults.

When the findings of that work are available next year—I believe that we expect it early in 2020—we will convene a short-life group that will include people with lived experience and clinicians to consider what practical steps we can take to make a difference in advance of the draft National Institute for Health and Care Excellence guideline. The group will consider what can be done ahead of the NICE guideline being available. I understand that NICE recently provided an update on the timing of its revised guideline on ME that postponed publication of the draft until July and the final version until December 2020. I know that that will be disappointing for those who are already frustrated by the wait, but I understand that the reason behind the delay is the need to take account of the additional work that NICE has commissioned on patient experience. In light of the recognised limitations on available clinical evidence and the calls for greater emphasis on lived experience, I hope that that reassures people that NICE is undertaking a comprehensive review of the latest evidence.

That is why we do not plan at this point to make any changes to the advice in the Scottish good practice statement on ME ahead of considering the NICE findings, including guidance on graded exercise therapy and cognitive behavioural therapy. Our previous submissions have set out the reasons for that but, to summarise, I note that those therapies are reported as being effective for some people, but not all. I note that, in the submissions that you have received from health boards, many refer specifically to the Scottish statement, which provides clear information about the appropriateness of and circumstances for using those therapies. We highlighted the Scottish statement to health boards when it was introduced and we will do that again if we update it.

In setting out all of that, I appreciate that there will be questions about the acceleration of progress. I recognise and share the frustration behind people’s need for change at pace, but it is important to ensure that change is enacted based on appropriate evidence and shared principles to support the co-production of services with those who are living with ME. That is why we have invested time to ensure that the work that we are commissioning is shaped by people with ME and the third sector organisations that represent them.

I hope that that was a helpful opening statement. We are, of course, very happy to take questions.

Johann Lamont Lab The Convener · Glasgow
link

Thank you for your statement. We received a further submission with some questions from the petitioner. I think that you have a copy of it. If we do not manage to cover those questions, we would appreciate it if you could respond to them at a later stage. The petitioner will be interested in your responses, but we might not be able to get through all of that now.

In your letter of 26 September, you said that the chief scientist office and the chief medical officer were to meet Action for ME and Professor Ponting in October to discuss the progress that is being made through the current project on biomedical research on ME. Can you provide an update on that?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

Given that the chief medical officer was involved in that, I am happy to ask her to respond.

Dr Catherine Calderwood Scottish Government
link

I met Professor Chris Ponting, who has a long interest in research on ME, and officials from the chief scientist office and Action for ME. We had a very helpful meeting and we discussed where the charity groups and support groups would like to go forward with research. The discussion focused on the priority-setting partnership with the James Lind Alliance. Under that well-known methodology for research prioritisation, if there are a number of requests for research, they are considered by a group of researchers from outside the speciality, who look at how research would be carried out in a prioritised way. We support calls for research on ME with people with lived experience and the charities that are involved, and the Scottish Government will enable some funding for the James Lind Alliance to go through that priority setting process. We will then need people to come forward with suggestions for the research.

Gail Ross SNP Caithness, Sutherland and Ross
link

Cabinet secretary, you mentioned in your submission and your opening statement that the Scottish Government continues to liaise with NES to explore opportunities to raise awareness of ME among healthcare professionals. Will you give us an update on the kinds of opportunities that you were referring to? Can you also give us an update on the letter that was sent to Sir Peter Rubin a year ago? Do you intend to follow up on that to find out what impact it has had?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

NES has a practice-based small group learning membership that includes general practitioners. That group has prioritised ME as a module for NES to produce in 2020-21. The intention was that the timing for that would be determined by the new NICE guideline publication, but I understand that it will do some advance work and will be able to make progress on the basis of the draft guideline that will appear in July 2020. When it produces the module, it will make sure that GPs in particular, as well as others, are aware of it, and we can back that up by encouraging health boards to draw the module to the attention of their relevant clinicians.

Sir Peter Rubin has shared the letter that was sent to him with the heads of the Scottish medical schools. As you know, undergraduate curricula are determined by individual medical schools and are quality assured by the General Medical Council. I had a meeting with our medical schools yesterday, at which we talked about the programme for government commitment on a new medical school. I have undertaken to meet the medical schools again early in the new year to pick up on a number of issues with them, including the one that we are discussing, as well as other aspects of the curriculum, widening access and so on. I will be very happy to update the committee following that further meeting.

The medical schools are aware of the work on ME and are currently giving some consideration to their curricula, but as you will appreciate, there are many demands on the curricula. It is partly a question of looking at some of the training placements that are offered to undergraduate medical students and potential training for foundation level graduates.

09:00

Gail Ross SNP Caithness, Sutherland and Ross
link

On continuing professional development of our medical staff, I was concerned that NHS Forth Valley said in its response that it sees the diagnosis of ME as a historical diagnosis. How can we make sure that doctors are diagnosing ME and not other diseases?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

That is not uncommon, to an extent, with neurological conditions. Yesterday, I had a discussion with some of our clinical advisers and colleagues on attention deficit hyperactivity disorder, for example, and I think that the right phrase—Dr Calderwood will correct me if I am wrong—is “neurodiversity”. There is a range of neurological conditions, of which there is a growing understanding among our clinicians.

Gail Ross SNP Caithness, Sutherland and Ross
link

But if the health board as a whole is not even recognising a diagnosis of ME, we are not talking about misdiagnosis; the board is simply refusing to diagnose it in the first place.

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

I understand what you are saying. In publishing the framework for action, we want to raise the issue directly with all those who have been involved through our regular contact with boards, chief executives and medical directors, and through Dr Calderwood’s network. In particular, we want to raise directly with NHS Forth Valley the response that it gave, which is out of line with what we would expect. We need to understand better from NHS Forth Valley why it is in that position and, more importantly, how it will address the situation and change things so that it is in line with all the other boards.

At the same time, there is a degree of inconsistency in how our boards respond, as I am sure that the committee has picked up. That is not unusual—the same applies in other areas. We need to look at where variation is acceptable and where it is not with a view to ensuring that there is a degree of consistency.

Maurice Corry Con West Scotland
link

I note the comments that you made in your opening statement, cabinet secretary. The committee understands that you have spoken to many stakeholders from the ME community to explore variation in the provision of services and the different practices that exist across Scotland. Can you give us an update on what progress has been made in the course of your meetings with stakeholders? You made a general reference to that earlier, but I would like to know what has come out of that process.

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

Part of the reason for commissioning the pieces of work by the Scottish Health Council and the Scottish public health network that I referred to towards the end of my introductory remarks is to understand the detail of various practices across the country and where the variation lies. I expect to have the results of that work early in 2020, at which point we will look at what the variation is and what we might do about it, so that we have a clear core patient pathway that runs alongside what Gail Ross was talking about—education and awareness in the clinical community.

Maurice Corry Con West Scotland
link

That will help to address NHS Forth Valley’s comments.

Thank you—I am happy with that.

Brian Whittle Con South Scotland
link

In January, the chief medical officer told the committee that the Scottish Government was creating a working group to look at the provision of services. You echoed that in your submission of 30 January 2019, and you mentioned the on-going work in your opening statement. However, in your most recent submission of 26 September 2019, you stated that the group would not start work until early 2020. Can you explain the reason for what seems to be a bit of a delay in the implementation of the short-life working group?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

Part of what the short-life working group will have to work with are the two pieces of work that I have commissioned, which will provide it with evidence on the range of services that exists. I will ask the CMO to update us on exactly how that group will be formed and the specific work that it will do.

Dr Calderwood
link

There will be some frustration about the delay, but we are starting from a baseline of very little data. We want to know about the number of people who have been diagnosed and to find out about the level of care across our health boards at the moment, or rather the variation in the provision of care, which has already been described.

As well as gathering evidence, we have written to all our health boards to ask about the education of healthcare practitioners. We did that in response to the comments that were made by NHS Forth Valley. We have had 10 responses out of the 14 health boards and, unfortunately, the education of healthcare professionals seems to vary a lot, as I suppose we might have expected, given the variation that we have found in other areas.

We have been gathering information to enable the working group to set some priorities and to start work. We could not just produce a group and then decide to get the evidence that was needed. We will work with that group, which will include people with lived experience and people from the ME charities, as well as Government officials and multidisciplinary healthcare professionals who are providing care across our health boards. We will take the data that we have—one of the next things that we will need to do is strengthen the collection of data—and the evidence on the range of pathways of care for patients right through to healthcare professionals’ education so that we can map out how we can follow best practice across Scotland and be consistent in all our health boards.

The NICE guidance is long awaited, as you know. There has been a further delay for good reason—to capture evidence from those with lived experience—but our working group will not be delayed by waiting for the new guidance, because we already know what work we have to do, as I have outlined. Once the NICE guidance is produced, we will be ready to go. We will have the draft guidance in July.

Brian Whittle Con South Scotland
link

Cabinet secretary, you mentioned in your opening statement the two pieces of work that the Scottish Government has commissioned. Forgive me if I missed this, but do you have a timescale for when you expect those pieces of work to be completed?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

You are referring to the updated needs assessment by the Scottish public health network and the Scottish Health Council’s work on what good care and support for people with ME would look like. I expect to have those pieces of work next year—early in 2020, I understand.

Brian Whittle Con South Scotland
link

What has the Scottish Government done to ensure that the ME community is kept up to date with the timescale and the developments that are in progress?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

A number of meetings have taken place between my officials and stakeholders in the ME community, including the petitioner. We will continue that process of keeping stakeholders up to date. They know all the information that I provided in my statement about the work that is under way, including what Dr Calderwood has mentioned, and the research discussions that are taking place through the chief scientist office. We will continue to keep stakeholders up to date as progress is made; they will, of course, be involved in much of this work as we develop it.

Johann Lamont Lab The Convener · Glasgow
link

I will reflect on some of the comments that have been made to us in submissions. In one anonymous submission, a person said that they did not feel there was any sense of urgency for change to relieve their suffering, and we have heard that from various people. In his submission, Stuart Brown concludes:

“ME patients have every reason to believe that the NHS doesn’t understand them, doesn’t care about them and has no intention of changing.”

Can you respond to that? It is a theme of the concerns that have been flagged up to us.

Specifically on the pacing, graded activity and cognitive behaviour therapy—PACE—trial, you suggested that you thought that there was some benefit from the treatments that are being offered, but one of the contentions from the petitioner and others is that not only are the treatments not beneficial—there is no evidence that they are beneficial—but if they are persisted with, they cause further problems in some circumstances.

Professor Brian Hughes has looked at the methodology on the PACE trial. It is probably beyond this committee to understand a lot of the technical details to do with methodology—I would certainly not want to pretend to be an expert on that—but what reassurance can you give us that such questions are being addressed through the national health service? Gail Ross made the point that some health boards are now saying that there is no such thing as ME and that the world has moved on. The difference in the approach of different health boards must undermine people’s confidence. I am not asking you to deal with the specifics of the issues that have been flagged up, but what reassurance can you give the committee that those concerns will be addressed?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

Thank you for that, convener. Your questions are important for those who are suffering from ME, and it is important for our wider clinical community to hear and understand my answers.

I completely understand the frustration that people feel about what they perceive to be a lack of urgency and pace in this work. The core reason behind that is partly what the CMO has already said and what I have said. As the committee knows, we need to move with pace on the basis of the data and the evidence that we gather. That is why the work that we have commissioned is so important, a significant amount of which we will have in the early part of 2020. The short-life group will have the data that the CMO has outlined so that it can begin to look at what good-quality care is.

I said at the outset that people who are suffering from ME have as much right as anyone else to consistent, high-quality care across the country. The piece of work that the Scottish Health Council is undertaking to understand what good looks like will be really important in mapping out what the right patient pathway would be for diagnosis, potential treatment and support. In parallel with that is the work with the clinical community that NES is leading, so that people’s understanding and awareness of ME as a neurological condition—I said this at the start and I want to repeat it—is well understood.

All of that is taking place in the context of our plan and the framework for action. It is important that the ME community knows that it has been involved in the construction of the plan, along with other stakeholders, and that it knows that we are very clear that ME is a neurological condition. If we have boards that believe that ME is a historical matter and that the world has moved on, we need to correct their understanding. We also need to ensure, through undergraduate and postgraduate training and continuing professional development, that our clinical community is aware and has a degree of understanding of how to distinguish between different neurological conditions in diagnosis, and that a consistent pathway is delivered across the country to provide the support that people need and are looking for. All of that is the end goal. To get there, we need to have the better data that we are currently trying to gather in order to map out the necessary steps.

09:15

We have said that the GET and CBT treatments are controversial treatments that certainly do not work for everyone; I completely understand that. It should not be the case that they are expected to be helpful and effective for everyone with a diagnosis of ME. I say again—we need to make sure that our clinicians understand this—that patients should be the drivers of decisions about the treatment that they are given or are prepared to undertake. When patients say, “This not only does not work for me but is positively unhelpful to me,” clinicians’ responsibility is to have that conversation and to see what else might be helpful, which might go beyond their immediate role to that of a wider multidisciplinary team. That is part of the work that we need to undertake.

Johann Lamont Lab The Convener · Glasgow
link

In its submission, NHS Lothian resists the critique of the PACE trial that has been provided by the ME community. The argument is that something should be built into the methodology that will bring about a conclusion that many in the ME community would not accept, which is what you have said about people not being expected to have various treatments. It is beyond the capacity of this committee to look at the technical details of that, but would the CMO and others at least look at that?

If we have a methodology that results in a conclusion that is then used as an argument against those who say that the treatment in question is not working for them, we can see where the problem is. I do not pretend to know who is right about this, but I would seek a commitment from you to look at what the petitioner and others who have criticised the PACE trial have said, and the response by NHS Lothian, to see whether you are ending up with an outcome that has come from something inside the trial. NHS Lothian’s response is very robust, but is that something that you would at least look at?

Dr Calderwood
link

Yes, I agree that we will need to look at that carefully. We could write to the committee. I can ask Chris Ponting and others to help me to look at the PACE trial. Like the cabinet secretary, I do not find it acceptable that patients are reporting that a certain treatment is unhelpful for them but are being encouraged to continue with it, with no other offer being made. We must work in partnership with patients and must share decision making with them. In all trials, there will be some patients who benefit and some who do not, and it disturbs me greatly to hear that patients are being forced to continue certain treatments before being offered an alternative, even when the treatment might not only be unhelpful but might be causing them side-effects and harm.

Johann Lamont Lab The Convener · Glasgow
link

Thank you very much for responding to our questions. We will have to reflect on what we have heard. If there are points on which you want to respond further, particularly the last point, that would be helpful. As there are no more questions, at this point we will simply agree to reflect on what we have heard today. People will be able to respond to what they have heard, and we will come to further conclusions on the petition at that stage.

Thank you very much for your attendance. I appreciate how early you had to be with us this morning. It has helped the work of the committee to be able to deal with the matter in that way. I wish you a happy Christmas.

I now suspend the meeting briefly.

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

Before you do that, convener, I would like to say that we will answer all the questions that the petitioner submitted on 17 December, and we will copy you into our answers so that you have our responses. I offer my best wishes to you all for Christmas.

Johann Lamont Lab The Convener · Glasgow
link

Thank you. I appreciate that.

09:20 Meeting suspended.

09:23 On resuming—

  1. 08:45 Continued Petitions Petitions · 28
  2. 09:15 Continued Petitions Petitions · 26
  3. 09:45 Continued Petitions Petitions · 41
  4. 10:30 Continued Petitions Petitions · 100

The type of each item (debate, statement, questions, members’ business and so on) and the times shown are worked out by this site from headings, the chair’s opening words and the Official Report’s running timestamps. They are not the Parliament’s own classification. Text: the Scottish Parliament Official Report.